Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma

BACKGROUND: Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable. However, preclinical experimental data explaining the interaction mechanism(s) are lacking. Our obj...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Lifen, Ren, Zhenggang, Jia, Qingan, Wu, Weizhong, Shen, Hujia, Wang, Yanhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734040/
https://www.ncbi.nlm.nih.gov/pubmed/23895220
http://dx.doi.org/10.1186/1471-2407-13-363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734040/
https://www.ncbi.nlm.nih.gov/pubmed/23895220
http://dx.doi.org/10.1186/1471-2407-13-363

Ejemplares similares